Physician profile
Rosa Robles
NPI 1588107817
$2,039.13
in general payments reported to CMS, 2019-2025
9 companies · $18.09 in 2025
The $18.09 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.69 · 2022: $431 · 2023: $711 · 2024: $858 · 2025: $18.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.76 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $764.77 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $694.93 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $291.07 | 2022-2024 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $114.51 | 2024 | Veozah |
| Exact Sciences Corporation | $61.15 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $42.59 | 2023 | |
| Glaxosmithkline, LLC. | $42.17 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Phadia US INC. | $20.32 | 2024 | Immunocap |
| Genentech USA, INC. | $7.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.